Recently, a growing number of studies support the use of 5-HT6R-targeting compounds as promising drug candidates for treating cognitive dysfunction associated with Alzheimer’s disease. This evidence concerns the gene HTR6 and early-onset autosomal dominant Alzheimer disease.